Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution and Brain Kinetics of 11C-JNJ-63779586
NCT03089918Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 11C-JNJ-63779586 (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Effective Radiation Dose Following Injection of 11C-JNJ-63779586 at Day 1, Total and Regional Brain Compartmental Kinetics for Volume of Distribution of 11C-JNJ-63779586 at Day 1 and 2 more. Started May 2017; status: completed.
02
Drugs
11C-JNJ-63779586
Beyond the preview
Go deeper on NCT03089918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089918.